soul trial oral semaglutide cardiovascular outcomes 2025 Pharmacy soul trial oral semaglutide cardiovascular

Dosing Information GLP-1 medication, semaglutide, is prescribed in doses that increase every 4 weeks

You should also not take semaglutide if you are pregnant and, if youre taking it post-delivery, its recommended you should not breastfeed

It's important to note that Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved for chronic weight management, while Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes management, though they may be used off-label for weight loss

Drugs like Ozempic, Wegovy, and Mounjaro reduce cravings and slow gastric emptying, leading to gradual weight loss

The incredible demand for Wegovy has resulted in its own supply issues and so now Ozempic is increasingly prescribed off-label for weight loss, rather than for diabetes, resulting in knock-on supply issues

Semaglutide affects the pancreas, GI tract, heart, brain, metabolism, and liver to promote weight loss